MCID: CNN010
MIFTS: 44

Connective Tissue Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

MalaCards integrated aliases for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 15
Soft Tissue Neoplasms 54 44 71
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12
Soft Tissue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 44 D012983
NCIt 50 C3377
SNOMED-CT 67 126600002
UMLS 71 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to chondroblastoma and fibroma. An important gene associated with Connective Tissue Benign Neoplasm is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Vincristine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, bone and liver, and related phenotypes are integument and muscle

Related Diseases for Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 chondroblastoma 32.1 USP6 TNFSF11 SERPINA3 H3-3B H3-3A H2AC18
2 fibroma 31.9 USP6 SERPINA3 PECAM1 CTNNB1 CDC73 CD68
3 bone benign neoplasm 31.7 USP6 TNFSF11 SERPINA3 H3-3B H3-3A CSF1
4 malignant giant cell tumor 31.1 H3-3B H3-3A CD68
5 neurilemmoma 31.1 SERPINA3 KIT CD34
6 chondrosarcoma 31.1 SERPINA3 MDM2 EWSR1 CDK4
7 liposarcoma 30.9 MDM2 EWSR1 CTNNB1 CDK4 CD68 CD34
8 malignant peripheral nerve sheath tumor 30.9 MLANA MDM2 KIT CDK4 CD34
9 dermatofibrosarcoma protuberans 30.9 SERPINA3 KIT CDK4 CD34
10 granular cell tumor 30.8 SERPINA3 MLANA CD68
11 clear cell sarcoma 30.8 MLANA KIT EWSR1
12 sarcoma 30.8 MDM2 KIT EWSR1 CTNNB1 CDK4
13 neurofibroma 30.8 MLANA KIT CD34
14 villonodular synovitis 30.8 CSF1 CD68
15 sarcoma, synovial 30.8 SERPINA3 MDM2 KIT H2AC18 EWSR1 CTNNB1
16 hemangioma 30.7 PECAM1 KIT CTNNB1 CD34
17 rhabdomyosarcoma 30.7 MDM2 KIT EWSR1 CTNNB1 CDK4
18 actinomycosis 30.7 PECAM1 H2AC18 CD68
19 spindle cell sarcoma 30.6 SERPINA3 MDM2 KIT EWSR1 CD34 CALD1
20 leiomyosarcoma 30.6 SERPINA3 PECAM1 MLANA MDM2 KIT CDK4
21 malignant granular cell myoblastoma 30.6 SERPINA3 MLANA CD68
22 pigmented villonodular synovitis 30.6 TNFSF11 SERPINA3 CSF1 CD68
23 infiltrating lipoma 30.6 MDM2 CDK4 CD34
24 myxoid liposarcoma 30.6 MDM2 EWSR1 CDK4
25 myositis ossificans 30.5 USP6 MDM2 CDK4
26 perivascular epithelioid cell tumor 30.5 MLANA KIT CALD1
27 pleomorphic lipoma 30.5 SERPINA3 MDM2 CDK4 CD68 CD34
28 plexiform schwannoma 30.5 KIT CD34
29 neuroma 30.5 SERPINA3 CD68 CD34
30 clear cell chondrosarcoma 30.5 SERPINA3 H3-3B H3-3A H2AC18
31 epithelioid sarcoma 30.4 PECAM1 CD68 CD34
32 rare tumor 30.4 KIT EWSR1
33 cutaneous fibrous histiocytoma 30.4 SERPINA3 MLANA CD68 CD34
34 benign giant cell tumor 30.4 TNFSF11 SERPINA3 H3-3B H3-3A CSF1
35 dedifferentiated liposarcoma 30.3 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
36 malignant fibrous histiocytoma 30.3 SERPINA3 MDM2 KIT EWSR1 CDK4 CD68
37 glomus tumor 30.3 PECAM1 KIT CD34 CALD1
38 inflammatory myofibroblastic tumor 30.3 MDM2 KIT CDK4 CD68 CD34 CALD1
39 hemangiopericytoma, malignant 30.2 SERPINA3 PECAM1 MDM2 KIT CD34 CALD1
40 fibrous histiocytoma 30.2 SERPINA3 PECAM1 KIT EWSR1 CD68 CD34
41 pseudosarcomatous fibromatosis 30.2 USP6 SERPINA3 PECAM1 KIT CTNNB1 CD68
42 angiosarcoma 30.2 PECAM1 MLANA KIT CD68 CD34
43 myxofibrosarcoma 30.1 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
44 well-differentiated liposarcoma 29.9 SERPINA3 MLANA MDM2 KIT EWSR1 CDK4
45 lipomatosis, multiple 29.8 SERPINA3 PECAM1 MLANA MDM2 KIT EWSR1
46 mesenchymal cell neoplasm 29.8 SERPINA3 PECAM1 MLANA KIT EWSR1 CD68
47 infantile myofibromatosis 11.2
48 desmoid tumor 11.2
49 spleen angiosarcoma 11.1
50 ring chromosome 7 10.5 MDM2 CDK4

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.96 CD34 CDC73 CDK4 CSF1 CTNNB1 KIT
2 muscle MP:0005369 9.76 CDC73 CDK4 CSF1 CTNNB1 KIT MDM2
3 neoplasm MP:0002006 9.56 CD34 CDC73 CDK4 CTNNB1 IRF4 KIT
4 no phenotypic analysis MP:0003012 9.17 CD68 CSF1 CTNNB1 KIT MDM2 MLANA

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Ifosfamide Approved Phase 3 3778-73-2 3690
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
7
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
8
Daunorubicin Approved Phase 3 20830-81-3 30323
9 Antirheumatic Agents Phase 3
10 Alkylating Agents Phase 3
11 Immunosuppressive Agents Phase 3
12 Keratolytic Agents Phase 3
13 Antibiotics, Antitubercular Phase 3
14 Etoposide phosphate Phase 3
15 Immunologic Factors Phase 3
16
Isophosphamide mustard Phase 3 100427
17 Dermatologic Agents Phase 3
18 Antimitotic Agents Phase 3
19 Anti-Bacterial Agents Phase 3
20 Tubulin Modulators Phase 3
21 Podophyllotoxin Phase 3 518-28-5
22 topoisomerase I inhibitors Phase 3
23
Liposomal doxorubicin Phase 3 31703
24 Immunoglobulins Phase 3
25 Antibodies Phase 3
26 Antibodies, Monoclonal Phase 3
27
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
28
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
29
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
30
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
31 Analgesics, Non-Narcotic Phase 2
32 Analgesics Phase 2
33 Vaccines Phase 2
34 Interleukin-2 Phase 2
35 Epinephryl borate Phase 1, Phase 2
36 Carboxymethylcellulose Sodium Phase 1, Phase 2
37 Radiopharmaceuticals Phase 2
38 Fluorodeoxyglucose F18 Phase 2
39
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
40
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
41
Bevacizumab Approved, Investigational Phase 1 216974-75-3
42
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030
44
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
45
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
46
Iodine Approved, Investigational Phase 1 7553-56-2 807
47
Cadexomer iodine Experimental Phase 1 94820-09-4
48 Liver Extracts Phase 1
49 Antifungal Agents Phase 1
50 Angiogenesis Inhibitors Phase 1

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
2 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
3 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
4 The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors Completed NCT00001189 Phase 2
5 SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES Completed NCT02066675 Phase 2 Trabectedin
6 A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS). Recruiting NCT04166006 Phase 2 Interleukin-2
7 Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors Active, not recruiting NCT02285439 Phase 1, Phase 2 MEK162
8 A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma Terminated NCT01169350 Phase 2
9 Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Unknown status NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
10 Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on. Completed NCT03159585 Phase 1 TAEST16001
11 A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies Recruiting NCT04370587 Phase 1
12 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
13 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
14 An Open, Single Arm and Early Clinical Study of TAEST16001 in the Treatment of Solid Tumor Mainly Containing Soft Tissue Sarcoma With Positive Expression of Tumor Antigen NY-ESO-1 (HLA-A * 02:01) Recruiting NCT04318964 Phase 1
15 A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Terminated NCT02602067 Phase 1
16 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
17 Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors Unknown status NCT03452644
18 Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002 Unknown status NCT00173355
19 Navigation Surgery for Bone and Soft Tissue Tumor Unknown status NCT01179698
20 Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors Unknown status NCT03751566 Standard supportive therapy
21 Follow-up of Recurrences of Limb Soft Tissue Sarcomas in Patients With Localized Disease: Performance of Ultrasound Unknown status NCT02834585
22 Osteoarticular Tumor Characterization by Advanced Imaging Unknown status NCT02895633
23 Feasibility of the Third Space Robotic and Endoscopic Cooperative Surgery(TS-RECS) for Treating Gastric Stromal Tumor Completed NCT03804762
24 Radiofrequency Ablation of Painful Soft Tissue Neoplasms Completed NCT00041886
25 Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt Completed NCT04300179
26 Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI Completed NCT01276483
27 Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study Completed NCT02557243
28 In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study Completed NCT01731379
29 Quantitative MR Biomarkers for Sarcoma Treatment Completed NCT01017978
30 Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors Completed NCT01630239 Early Phase 1
31 Development of an MRI-based Radiomic Model for Non-invasive Tumor Grading of Soft Tissue Sarcomas. Completed NCT03798795
32 Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II: Texture Analysis and Artificial Intelligence Recruiting NCT04394052
33 Clinical Performance Investigation of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Soft Tissue Removal During Urological and General Surgery Recruiting NCT04298268
34 A Pilot Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin and Superficial Soft Tissue Tumors Recruiting NCT04377360
35 A Safety and Efficacy Study of Retreatment With Intratumoral Diffusing Alpha Radiation Emitters Recruiting NCT04540588
36 An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Recruiting NCT02677961
37 Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma Recruiting NCT02561559
38 The Impact of Pecs Blocks on the Appearance of Post Mastectomy Chronic Pain Symptoms Recruiting NCT04586751
39 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT03889899
40 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT03737734
41 A Pilot Study of Photoacoustic Imaging (PAI) Recruiting NCT03630601
42 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT04534127
43 Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma Recruiting NCT03896620 Chemotherapy
44 Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites. Active, not recruiting NCT00582647
45 A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia Not yet recruiting NCT03886181
46 A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities Terminated NCT01965002 Aspirin;Enoxaparin
47 Prospective Multi-center National Swiss Sarcoma Cohort Study Terminated NCT02775799
48 The Use of Liposomal Bupivacaine (Exparel) in Soft Tissue Sarcoma Resection Terminated NCT03867188 Early Phase 1 Liposomal Bupivacaine

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 51 :


docetaxel

Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

19
Connective Tissue

MalaCards organs/tissues related to Connective Tissue Benign Neoplasm:

40
Bone, Liver, Skin, Endothelial, Prostate, Nk Cells, Thyroid

Publications for Connective Tissue Benign Neoplasm

Articles related to Connective Tissue Benign Neoplasm:

(show top 50) (show all 506)
# Title Authors PMID Year
1
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 61 54
16707369 2006
2
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 54 61
16160477 2005
3
Advances in the Diagnosis and Management of Neonatal Sarcomas. 61
33583500 2021
4
Abrikossoff Tumor (Granular Cell Tumor) Presenting in the Esophagus. 61
33604226 2021
5
Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms. 61
33608696 2021
6
Diagnostic yield and safety of percutaneous CT-guided biopsy of retroperitoneal lesions and analysis of imaging features. 61
33530697 2021
7
Imaging of the lesions in the lateral muscle compartment of the forearm, alias mobile wad of Henry: Demographics, radiological anatomy and surgical relevance. 61
33075596 2021
8
Unilateral lower limb atrophy associated with glomus tumors: a case report. 61
33436045 2021
9
Case for diagnosis. Dorsal nodule in a 10-year-old male. 61
33579582 2021
10
Tumours in European Shorthair cats: a retrospective study of 680 cases. 61
32048893 2020
11
Whole-exome sequencing reveals novel vacuolar ATPase genes' variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. 61
33289181 2020
12
Benign connective and soft-tissue neoplasms of the oral and maxillofacial region: A cross-sectional study of 1066 histopathological specimens. 61
33340377 2020
13
The value of bi-exponential and non-Gaussian distribution diffusion-weighted imaging in the differentiation of recurrent soft tissue neoplasms and post-surgical changes. 61
33313102 2020
14
Treatment of intramuscular lipoma of tongue with enveloped mucosal flap design: a case report and review of the literature. 61
33296044 2020
15
Surgical Resection of a Symptomatic Superior Vena Cava Lipoma: A Case Report and Literature Review. 61
33160057 2020
16
Diagnostic Utility of a Custom 34-Gene Anchored Multiplex PCR-Based Next-Generation Sequencing Fusion Panel for the Diagnosis of Bone and Soft Tissue Neoplasms With Identification of Novel USP6 Fusion Partners in Aneurysmal Bone Cysts. 61
33147323 2020
17
Clinicopathological and molecular characterisation of USP6-rearranged soft tissue neoplasms: the evidence of genetic relatedness indicates an expanding family with variable bone-forming capacity. 61
33000481 2020
18
A Case of Synchronous Malignant and Benign Granular Cell Tumor of the Vulva. 61
32947331 2020
19
[Fine-needle biopsy of soft-tissue neoplasms: Case No.1]. 61
32340755 2020
20
Extraskeletal myxoid chondrosarcoma: combining cytopathology with molecular testing to achieve diagnostic accuracy. 61
32828707 2020
21
Giant Granular Cell Tumor of the Cervical Spinal Cord Resected via Anterior Corpectomy with Reconstruction: Technical Note and Review of Literature. 61
32283320 2020
22
Power Doppler in musculoskeletal ultrasound: uses, pitfalls and principles to overcome its shortcomings. 61
32683646 2020
23
SWI/SNF complex-deficient soft tissue neoplasms: An update. 61
32646614 2020
24
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. 61
31913156 2020
25
Desmoplastic stromal changes in cutaneous neural granular cell tumors: An under-recognized histopathologic feature of diagnostic and prognostic importance. 61
31859431 2020
26
Soft tissue tumor diagnosis: A three prong approach utilizing pattern analysis, immunocytochemistry, and molecular diagnostics. 61
31868988 2020
27
Bone Sarcomas and Desmoids. 61
31739943 2020
28
Genomic and transcriptomic features of dermatofibrosarcoma protuberans: Unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development. 61
31870844 2020
29
Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma? 61
31889532 2020
30
Duodenal angiosarcoma can be misdiagnosed as a Dieulafoy's lesion. 61
32821359 2020
31
Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center. 61
33061792 2020
32
Frontoethmoidal mucocele causing proptosis and visual loss. 61
33041590 2020
33
What is new in epithelioid soft tissue tumors? 61
31686193 2020
34
GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. 61
31189998 2019
35
Skin and superficial soft tissue neoplasms with multinucleated giant cells: Clinical, histologic, phenotypic, and molecular differentiating features. 61
31306855 2019
36
Is MRI diffusion-weighted imaging a reliable tool for the diagnosis and post-therapeutic follow-up of extremity soft tissue neoplasms? 61
31949339 2019
37
PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. 61
31008539 2019
38
Asymptomatic esophageal glomus tumor: case report. 61
31602340 2019
39
Isolated Breast Relapse after Metastatic Alveolar Rhabdomyosarcoma in a Young Premenarcheal Girl: What Could Have Been Done? 61
31911774 2019
40
Diffusion-weighted imaging and diffusion tensor imaging as adjuncts to conventional MRI for the diagnosis and management of peripheral nerve sheath tumors: current perspectives and future directions. 61
30535638 2019
41
Prevalence of Neoplasms among Former Adolescent Psychiatric Inpatients. 61
31389225 2019
42
[Myxoid soft tissue tumours : An algorithm for differential diagnosis]. 61
31168638 2019
43
[Clinicopathological characteristics and differential diagnosis of interdigitating dendritic cell sarcoma]. 61
31216832 2019
44
MRI imaging of soft tissue tumours of the foot and ankle. 61
31161474 2019
45
Spindle Cell Sarcoma of the Paraspinal Musculature with Late Pulmonary Metastases. 61
31186400 2019
46
Mesenchymal Tumors with EWSR1 Gene Rearrangements. 61
30709442 2019
47
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. 61
30853708 2019
48
SWI/SNF Complex-Deficient Soft Tissue Neoplasms: A Pattern-Based Approach to Diagnosis and Differential Diagnosis. 61
30709441 2019
49
Practical Application of Cytology and Core Biopsy in the Diagnosis of Mesenchymal Tumors. 61
30709446 2019
50
Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. 61
30350361 2019

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

GO Terms for Connective Tissue Benign Neoplasm

Cellular components related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.63 PECAM1 MDM2 H3-3B H3-3A CTNNB1 CDK4
2 Barr body GO:0001740 8.96 H3-3B H3-3A
3 nucleosome GO:0000786 8.92 IRF4 H3-3B H3-3A H2AC18

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 spermatid development GO:0007286 9.71 KIT H3-3B H3-3A
2 hemopoiesis GO:0030097 9.7 KIT CTNNB1 CD34
3 negative regulation of neuron death GO:1901215 9.69 CTNNB1 CSF1 CD34
4 stem cell population maintenance GO:0019827 9.63 KIT CTNNB1 CDC73
5 positive regulation of gene expression GO:0010628 9.63 TNFSF11 MDM2 KIT CTNNB1 CSF1 CD34
6 paracrine signaling GO:0038001 9.49 TNFSF11 CD34
7 endodermal cell fate commitment GO:0001711 9.48 CTNNB1 CDC73
8 pericentric heterochromatin assembly GO:0031508 9.43 H3-3B H3-3A
9 osteoclast differentiation GO:0030316 9.43 TNFSF11 CTNNB1 CSF1
10 osteoclast proliferation GO:0002158 9.4 TNFSF11 CSF1
11 regulation of centromere complex assembly GO:0090230 9.37 H3-3B H3-3A
12 glomerular endothelium development GO:0072011 9.32 PECAM1 CD34
13 negative regulation of chromosome condensation GO:1902340 8.96 H3-3B H3-3A
14 telomeric heterochromatin assembly GO:0031509 8.62 H3-3B H3-3A

Molecular functions related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 USP6 TNFSF11 SERPINA3 PECAM1 MLANA MDM2

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....